181 related articles for article (PubMed ID: 36185261)
21. Efficacy of dacomitinib in patients with non-small cell lung cancer carrying complex
Li HS; Li JL; Yan X; Xu HY; Zhou LQ; Hu XS; Wang YY; Lei SY; Wang Y
J Thorac Dis; 2022 May; 14(5):1428-1440. PubMed ID: 35693621
[TBL] [Abstract][Full Text] [Related]
22. Rationale and design of a phase II study to evaluate prophylactic treatment of dacomitinib-induced dermatologic adverse events in epidermal growth factor receptor-mutated advanced non-small cell lung cancer (SPIRAL-Daco study).
Iwasaku M; Uchino J; Yamada T; Chihara Y; Shimamoto T; Tamiya N; Kaneko Y; Kiyomi F; Takayama K
Transl Lung Cancer Res; 2019 Aug; 8(4):519-523. PubMed ID: 31555524
[TBL] [Abstract][Full Text] [Related]
23. Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).
Gelatti ACZ; Drilon A; Santini FC
Lung Cancer; 2019 Nov; 137():113-122. PubMed ID: 31568888
[TBL] [Abstract][Full Text] [Related]
24. Remarkable response to dacomitinib in a patient with leptomeningeal carcinomatosis due to EGFR-mutant non-small cell lung cancer.
Mizusaki S; Otsubo K; Ninomiya T; Arimura H; Tsuchiya-Kawano Y; Inoue K
Thorac Cancer; 2021 Jan; 12(1):114-116. PubMed ID: 33112047
[TBL] [Abstract][Full Text] [Related]
25. Causality Evaluation of Drug-Induced Liver Injury in Newborns and Children in the Intensive Care Unit Using the Updated Roussel Uclaf Causality Assessment Method.
Ye L; Feng Z; Huang L; Guo C; Wu X; He L; Tan W; Wang Y; Wu X; Hu B; Li T; Yang G; Chengxian G; He Q
Front Pharmacol; 2021; 12():790108. PubMed ID: 34987403
[No Abstract] [Full Text] [Related]
26. Real-World Data of Tigecycline-Associated Drug-Induced Liver Injury Among Patients in China: A 3-year Retrospective Study as Assessed by the Updated RUCAM.
Shi X; Zuo C; Yu L; Lao D; Li X; Xu Q; Lv Q
Front Pharmacol; 2021; 12():761167. PubMed ID: 34795591
[No Abstract] [Full Text] [Related]
27. Response to dacomitinib in advanced non-small-cell lung cancer harboring the rare delE709_T710insD mutation: A case report.
Xu F; Xia ML; Pan HY; Pan JW; Shen YH
World J Clin Cases; 2022 Jun; 10(17):5916-5922. PubMed ID: 35979118
[TBL] [Abstract][Full Text] [Related]
28. A case report of a drug-induced liver injury (DILI) caused by multiple antidepressants with causality established by the updated Roussel Uclaf causality assessment method (RUCAM) and in vitro testing.
González-Muñoz M; Monserrat Villatoro J; Marín-Serrano E; Stewart S; Bardón Rivera B; Marín J; Martínez de Soto L; Seco Meseguer E; Ramírez E
Clin Case Rep; 2020 Dec; 8(12):3105-3109. PubMed ID: 33363890
[TBL] [Abstract][Full Text] [Related]
29. Utility of Lymphocyte Transformation Test for Assisting Updated Roussel Uclaf Causality Assessment Method in Drug-Induced Liver Injury: A Case-Control Study.
Rodríguez A; García-García I; Martínez de Soto L; Gómez López De Las Huertas A; Borobia AM; González-Torbay A; Akatbach-Bousaid I; González-Muñoz M; Ramírez E
Front Pharmacol; 2022; 13():819589. PubMed ID: 35370653
[No Abstract] [Full Text] [Related]
30. Rationale and design of a phase II trial of dacomitinib in advanced non-small cell lung cancer patients with uncommon epidermal growth factor receptor mutations: a prospective and single arm study (DANCE study).
Zhang B; Shi C; Gao Z; Zhong H; Xiong L; Gu A; Wang W; Chu T; Zhang W; Wang H; Zhang X; Zhong R; Han B
BMC Cancer; 2022 Mar; 22(1):294. PubMed ID: 35305596
[TBL] [Abstract][Full Text] [Related]
31. Successful treatment of 2 patients with brain metastases from non-small cell lung cancer with epidermal growth factor receptor mutation receiving dacomitinib: A case report.
Zhao S; Cong X; Liu Z
Medicine (Baltimore); 2021 Jul; 100(30):e26680. PubMed ID: 34397694
[TBL] [Abstract][Full Text] [Related]
32. Hepatotoxicity with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer patients: A network meta-analysis.
Wu Z; Chen S; Du X; Wu Y; Xie X
J Clin Pharm Ther; 2021 Apr; 46(2):310-318. PubMed ID: 33031574
[TBL] [Abstract][Full Text] [Related]
33. An Update on Drug-induced Liver Injury.
Devarbhavi H
J Clin Exp Hepatol; 2012 Sep; 2(3):247-59. PubMed ID: 25755441
[TBL] [Abstract][Full Text] [Related]
34. The cost-effectiveness of dacomitinib in first-line treatment of advanced/metastatic epidermal growth factor receptor mutation-positive non-small-cell lung cancer (
Nilsson FOL; Gal P; Houisse I; Ivanova JI; Asanin ST
J Med Econ; 2021; 24(1):447-457. PubMed ID: 33754924
[TBL] [Abstract][Full Text] [Related]
35. Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials.
Ramalingam SS; O'Byrne K; Boyer M; Mok T; Jänne PA; Zhang H; Liang J; Taylor I; Sbar EI; Paz-Ares L
Ann Oncol; 2016 Mar; 27(3):423-9. PubMed ID: 26768165
[TBL] [Abstract][Full Text] [Related]
36. Drug Induced Liver Injury Attributed to a Curcumin Supplement.
Imam Z; Khasawneh M; Jomaa D; Iftikhar H; Sayedahmad Z
Case Rep Gastrointest Med; 2019; 2019():6029403. PubMed ID: 31781418
[TBL] [Abstract][Full Text] [Related]
37. Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations.
Mok TS; Cheng Y; Zhou X; Lee KH; Nakagawa K; Niho S; Lee M; Linke R; Rosell R; Corral J; Migliorino MR; Pluzanski A; Sbar EI; Wang T; White JL; Wu YL
J Clin Oncol; 2018 Aug; 36(22):2244-2250. PubMed ID: 29864379
[TBL] [Abstract][Full Text] [Related]
38. Drug idiosyncrasy due to pirfenidone presenting as acute liver failure: Case report and mini-review of the literature.
Verma N; Kumar P; Mitra S; Taneja S; Dhooria S; Das A; Duseja A; Dhiman RK; Chawla Y
Hepatol Commun; 2018 Feb; 2(2):142-147. PubMed ID: 29404521
[TBL] [Abstract][Full Text] [Related]
39. Dacomitinib in the Management of Advanced Non-Small-Cell Lung Cancer.
Lau SCM; Batra U; Mok TSK; Loong HH
Drugs; 2019 Jun; 79(8):823-831. PubMed ID: 31069718
[TBL] [Abstract][Full Text] [Related]
40. A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinib.
Reckamp KL; Giaccone G; Camidge DR; Gadgeel SM; Khuri FR; Engelman JA; Koczywas M; Rajan A; Campbell AK; Gernhardt D; Ruiz-Garcia A; Letrent S; Liang J; Taylor I; O'Connell JP; Jänne PA
Cancer; 2014 Apr; 120(8):1145-54. PubMed ID: 24501009
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
